Advertisement

Family Medicine pp 1116-1126 | Cite as

Selected Disorders of the Blood and Hematopoietic System

  • Paul M. Paulman
  • Layne A. Prest
  • Cheryl Abboud

Abstract

Hemophilia A is an autosomal recessive X-linked deficiency of factor VIII. Because of the mode of transmission and gene expression, males have hemophilia A, and females are usually asymptomatic carriers of the hemophilia A gene. All daughters of a hemophiliac father are carriers of the hemophilia A gene; all his sons are normal. The children of a female hemophilia A carrier have a 50% chance of being affected by the gene. Hemophilia A affects approximately 1/10,000 to 1/20,000 males in the United States.1

Keywords

Multiple Myeloma Sickle Cell Anemia Sickle Cell Disseminate Intravascular Coagulation Polycythemia Vera 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Monsour PA, Kruger BJ, Harden PA. Prevalence and detection of patients with bleeding disorders. Aust Dent J 1986; 31:103–11.CrossRefGoogle Scholar
  2. 2.
    Williams WJ, Beutler E, Erslev AJ, Lichtman MA. Hematology. New York: McGraw-Hill, 1990.Google Scholar
  3. 3.
    Association of Hemophilia Clinic Directors of Canada. Hemophilia and von Willebrand’s disease. 2. Management. Can Med Assoc J 1995;153:147–57.Google Scholar
  4. 4.
    Brocker-Briende AJHT, Briët E, Quadt R. Gentoype assignment of hemophilia A by use of intragenic and extragenic restriction fragment length polymorphisms. Thromb Hae-most 1987;57:131–6.Google Scholar
  5. 5.
    Leahey M, Wright LM. Intervening with families with chronic illness. Farn Syst Med 1985;3:60–9.CrossRefGoogle Scholar
  6. 6.
    Bowie EJW, Didishem P, Thompson JH, Owen CA. von Willebrand’s disease: a critical review. Hematol Rev 1968; 1:1–50.Google Scholar
  7. 7.
    Batlle J, Fernanda M, Lopez-Fernandez F, et al. Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals. Blood 1987;70:173–6.PubMedGoogle Scholar
  8. 8.
    Bertina RM, Van Der Marel-Van Nieuwkoop W, Dubbeldam J, Boekhout-Musser J, Verltkamp JJ. New method for the rapid detection of vitamin K deficiency. Clin Chim Acta 1980;105:93–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Committee on Nutrition. Vitamin K supplementation for infants receiving milk substitute infant formulas and for those with fat malabsorption. Pediatrics 1971;48:483–6.Google Scholar
  10. 10.
    Thorp JA, Gaston L, Caspers DR, Pal ML. Current concepts and controversies in the use of vitamin K. Drugs 1995;49: 376–87.PubMedCrossRefGoogle Scholar
  11. 11.
    DiFino SM, Lâchant NA, Kirshner JJ, Gottlieb AJ. Adult idiopathic thrombocytopenic purpura: clinical findings and response to therapy. Am J Med 1980;59:430–42.CrossRefGoogle Scholar
  12. 12.
    Akwari OE, Itani KMF, Coleman RE, Rosse WE Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP): current criteria for patient selection and results. Ann Surg 1987;206:529–39.PubMedCrossRefGoogle Scholar
  13. 13.
    Nalli G, Sajeva R, Carnevale MG, Ascari E. Danazol therapy for idiopathic thrombocytopenic purpura (ITP). Haemato-logica 1988;73:55–7.Google Scholar
  14. 14.
    Blanchette VS, Hogan VA, McCombie NE, et al. Intensive plasma exchange therapy in ten patients with idiopathic thrombocytopenic purpura. Transfusion 1984;24:388–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Clarkson SB, Bussel JB, Kimberly RP, et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc receptor antibody. N Engl J Med 314:1236–9.Google Scholar
  16. 16.
    Bird RM, Hammarsten JF, Marshall RA, Robinson RR. A study of hereditary hemorrhagic telangiectasia. N Engl J Med 1957;275:105–9.CrossRefGoogle Scholar
  17. 17.
    Tattersall RN, Seville R. Senile purpura. Q J Med 1950;19: 151–9.Google Scholar
  18. 18.
    Levinsky RJ, Barratt TM. IgA immune complexes in Henoch-Schönlein purpura. Lancet 1979;2:1100–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Szelid Z, Bereczky J, Nagymanyai Z, Ruszinhow V. Heparin prophylaxis of Henoch-Schönlein nephropathy. Acta Paediatr Hung 1986;27:57–60.PubMedGoogle Scholar
  20. 20.
    Lackner H, Karpatkin S. On the “easy bruising” syndrome with normal platelet count: a study of 75 patients. Ann Intern Med 1975;83:190–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Coleman RW, Robboy SJ, Minna JD. Disseminated intravascular coagulation (DIC): an approach. Am J Med 1972;52: 679–89.CrossRefGoogle Scholar
  22. 22.
    Williams WJ, Beutler E, Erslev AJ, Lichtman MA. Hematology. New York: McGraw-Hill, 1990.Google Scholar
  23. 23.
    Dale DC, Guerry D, Wewerka JR, Bull JM, Cusid MJ. Chronic neutropenia. Medicine (Baltimore) 1979;58:128–44.Google Scholar
  24. 24.
    Murphy MF, Metcalfe P, Waters AH, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human and immunodeficiency virus infection. Br J Haematol 1987;66:337–40.PubMedCrossRefGoogle Scholar
  25. 25.
    Pincus SH, Boxer LA, Stossel TP. Chronic neutropenia in childhood. Am J Med 1976;61:849–61.PubMedCrossRefGoogle Scholar
  26. 26.
    Conway LT, Clay ME, Kline WE, Ramsay NKC, Krivit W, McCullough J. Natural history of primary autoimmune neutropenia in infancy. Pediatrics 1987;79:728–33.PubMedGoogle Scholar
  27. 27.
    Bussel J, Lalezari P, Fikrig S. Intravenous treatment with gammaglobulin of autoimmune neutropenia of infancy. J Pediatr 1988;112:298–301.PubMedCrossRefGoogle Scholar
  28. 28.
    Lalevari P, Murphy GB, Allen FH. NBI, a new neutrophil-specific antigen involved in the pathogenesis of neonatal neutropenia. J Clin Invest 1971;50:1108–15.CrossRefGoogle Scholar
  29. 29.
    Minchinton RM, McGrath KM. Alloimmune neonatal neutropenia—a neglected diagnosis. Med J Aust 1987;147:139–41.PubMedGoogle Scholar
  30. 30.
    Dale DC, Hammond WP. Cyclic neutropenia: a clinical review. Blood Rev 1988;2:178–85.PubMedCrossRefGoogle Scholar
  31. 31.
    Williams WJ, Beutler E, Erslev AV, Lichtner MA. Hematology. New York: McGraw-Hill, 1990.Google Scholar
  32. 32.
    Motulsky AG. Hemochromatosis. In: Wyngaarden JB, Smith LH, editors. Cecil textbook of medicine. 18th ed. Philadelphia: Saunders, 1988:1189–92.Google Scholar
  33. 33.
    Williams WJ, Beutler E, Erslev AV, Lichtner MA. Hematology. New York: McGraw-Hill, 1990.Google Scholar
  34. 34.
    Modan B. An epidemiological study of polycythemia vera. Blood 1965;26:657–67.PubMedGoogle Scholar
  35. 35.
    Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984;64:1–12.PubMedGoogle Scholar
  36. 36.
    Yu TF. Secondary gout associated with myeloproliferative diseases. Arthritis Rheum 1965;8:765–71.PubMedCrossRefGoogle Scholar
  37. 37.
    Brodsky I. Busulphan treatment of polycythemia vera. Br J Haematol 1982;52:1–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Dean J, Schecter AN. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches. N Engl J Med 1978; 299:752–63.PubMedCrossRefGoogle Scholar
  39. 39.
    Heller P, Best WR, Nelson RB, Becktel J. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Engl J Med 1979;18:1001–5.CrossRefGoogle Scholar
  40. 40.
    Dunston T, Rowland R, Huntsman RG, Yawson G. Sickle-cell haemoglobin C disease and sickle-cell beta thalassemia in white South Africans. S Afr Med J 1972;46:1423–6.PubMedGoogle Scholar
  41. 41.
    Powars DR. Natural history of sickle cell disease—the first ten years. Semin Hematol 1975;12:267–85.PubMedGoogle Scholar
  42. 42.
    Kark JA, Posey DM, Schumacher HR, Ruchle CJ. Sickle-cell trait as a risk factor for sudden death in physical training. N Engl J Med 1987;317:781–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Vermylen C, Robles EF, Ninance J, Cornu G. Bone marrow transplantation in five children with sickle-cell anemia. Lancet 1988;1:1427–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Charache S, Tevin MC, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. N Engl J Med 1995;332:1318–22.CrossRefGoogle Scholar
  45. 45.
    Levitan M. Textbook of human genetics. 3rd ed. New York: Oxford University Press, 1988.Google Scholar
  46. 46.
    Penn P. Coalitions and binding interactions in families with chronic illness. Farn Syst Med 1983;1:16–25.CrossRefGoogle Scholar
  47. 47.
    Leahey M, Wright LM. Interviewing with families with chronic disease. Farn Syst Med 1985;3:60–9.CrossRefGoogle Scholar
  48. 48.
    Moscinskil B. Of recent progress in multiple myeloma. Hematol Oncol 1994;12:111–23.CrossRefGoogle Scholar
  49. 49.
    Koettler HP, editor. Myelodysplastic syndrome. Hematol Oncol Clin North Am 1992;6:485–728.Google Scholar
  50. 50.
    Hoffebrand AV, Pettit JE, editors. The acute leukemias and chronic leukemias. In: Essential haematology. Oxford: Black-well, 1993;209–50.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Paul M. Paulman
  • Layne A. Prest
  • Cheryl Abboud

There are no affiliations available

Personalised recommendations